Vicore Pharma: Q4 Comment

Research Note

2021-03-01

07:20

Redeye notes that the Q4 report from Vicore did not include any major surprises. We provide a brief comment on the financials and highlight the most important events during the period. Our Base case remains at SEK 62 per share.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.